{"id":"fespixon-cream","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fespixon cream is a marketed topical formulation developed for dermatological use, likely containing active ingredients that support wound healing processes. The exact molecular mechanism is not well-documented in widely available literature, but topical formulations of this type typically work through reducing inflammation, preventing infection, and promoting epithelialization of damaged skin.","oneSentence":"Fespixon is a topical cream formulation designed to promote wound healing and tissue repair through anti-inflammatory and antimicrobial properties.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:30:25.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wound healing and tissue repair (specific indications not clearly documented in available sources)"}]},"trialDetails":[{"nctId":"NCT05322525","phase":"PHASE4","title":"A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.","status":"TERMINATED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-06-23","conditions":"Venous Leg Ulcers (VLU)","enrollment":9},{"nctId":"NCT05438251","phase":"PHASE4","title":"Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)","status":"TERMINATED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2022-08-04","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":3},{"nctId":"NCT05317442","phase":"PHASE4","title":"Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound","status":"TERMINATED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2022-04-06","conditions":"Pressure Injury Stage 2","enrollment":10},{"nctId":"NCT05338463","phase":"PHASE4","title":"Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients","status":"COMPLETED","sponsor":"Cathay General Hospital","startDate":"2021-12-01","conditions":"Chronic Diabetic Foot Ulcer","enrollment":5},{"nctId":"NCT05271708","phase":"PHASE4","title":"Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery","status":"COMPLETED","sponsor":"National Defense Medical Center, Taiwan","startDate":"2022-01-05","conditions":"Scar","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ON101 cream","ON101 Cream"],"phase":"marketed","status":"active","brandName":"Fespixon cream","genericName":"Fespixon cream","companyName":"National Defense Medical Center, Taiwan","companyId":"national-defense-medical-center-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fespixon is a topical cream formulation designed to promote wound healing and tissue repair through anti-inflammatory and antimicrobial properties. Used for Wound healing and tissue repair (specific indications not clearly documented in available sources).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}